Prostatitis is one of the most common illnesses in young men with different clinical presentations such as pelvic pain, lower urinary tract symptoms or sexual dysfunction and a high impact on their quality of life. The management of prostatitis patients is still today a challenge for the urologist and the general practitioner. Recent acquisitions in terms of epidemiological data and the latest classification from the NIH have triggered better management of the prostatitis patient, but there are holes in our knowledge about the pathophysiology, pathogenesis, and causative pathogens which can make it difficult to find the best treatment for our patients. On the one hand, the need for improved knowledge is demonstrated by the high number of patients who drop out from scheduled treatment. On the other hand, a high number of phytotherapeutic compounds have been introduced in the pharmacopeia and on the market with interesting results. The comprehension of the role of biofilm-producing bacteria and the use of antibiotics that are able to destroy them are important key points to consider. Finally, the andrological consequences, such as erectile dysfunction and premature ejaculation, must be adequately treated in order to improve the patients’ quality of life.